The XBI has plunged 27% since Donald Trump won the election, leaving the public markets an ugly mess for a biotech industry ...

Roche plans $50B investment in US over 5 years for R&D and manufacturing, including 4 new facilities and expansions, amid ...

AstraZeneca/Daiichi's Enhertu plus Perjeta shows better progression-free survival vs standard care in first-line HER2+ ...

Chinese biotech HuidaGene reports early success with first CRISPR brain treatment in 9-year-old with MECP2 duplication ...

Alvogen plans to fight a court decision that could significantly delay its ability to bring a generic version of Bausch ...

Gilead's antibody-drug conjugate Trodelvy combined with Merck's Keytruda reduced the risk of disease progression or death in ...